|
||||||||||
| DVT Awareness | Join Our Email List | Thursday, September 02, 2010 | ||||||||||
Find Information on a:
View all Postings for:
Search ClotCare
|
Low Molecular Weight Heparin Better than Graduated Compression Stockings for Preventing Venous Thrombosis in Knee Arthroscopy
Henry I. Bussey, Pharm.D., FCCP, FAHA Low molecular weight heparin (LMWH) prophylaxis for 7 days should be offered to low risk patients who are undergoing knee arthroscopy with meniscectomy - that is the conclusion of the authors of the largest study ever performed in preventing venous thromboembolism (VTE) in knee arthroscopy; and that is the conclusion of the insightful editorial by Russell Hull. Following arthroscopy, patients in this Italian study were randomly assigned to full leg graduated compression stockings (GCS at 30 to 40 mm Hg) [n= 660], low molecular weight heparin (LMWH, nadroparin 3800 anti-Xa units once daily for 7 days) [n = 657], or the same dose of nadroparin for 14 days [n = 444]. The 14 day regimen was discontinued for safety reasons at the 2nd interim analysis. Bilateral full-leg ultrasonography was done at the completion of the prophylaxis period and/or as indicated. Suspected pulmonary embolism (PE) was evaluated by V/Q scan, which was followed by chest CT if the V/Q results were "non-diagnostic". Patients with normal findings were followed for 3 months. The primary results, as presented in the attached table, indicated that the LMWH was superior to GCS in preventing thrombosis without a significant increase in major and clinically relevant bleeding. Click here to view the table.Additional key considerations:
The accompanying editorial by Russell Hull highlights the previous low grade recommendations found in various guidelines which are necessarily based on very limited data. Hull goes on to agree that the new findings encourage the use of LMWH prophylaxis for 7 days in "low risk" knee arthroscopy patients undergoing meniscectomy. For those not under-going meniscectomy the benefit is less clear; and for those at higher risks, the best regimen remains uncertain. References
|
|||||||||
|
Copyright 2000-2010 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information Send comments to webmaster@clotcare.org. ClotCare is a charitable 501(c)(3) non-profit organization. Click here to donate. |
||||||||||